ASH 2018: Daratumumab Improves Outcomes in Fragile Patients With Multiple Myeloma
Newly-diagnosed patients ineligible for transplant had greater progression-free survival and a lower risk of death with the addition daratumumab to standard therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.